Protocol Ledger

NCT05852938 · Phase III · ACTIVE NOT RECRUITING

A Study of Zigakibart in Adults With IgA Nephropathy

Interventional Phase III clinical trial protocol NCT05852938 sponsored by Novartis in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-06 Enrollment: 383 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05852938
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)383 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05852938
Protocol FieldVerified Registry Value
NCT IdentifierNCT05852938
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment383 participants (ACTUAL)
Registered Start Date2023-07-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI